BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 16050569)

  • 1. Advances in the early detection of ovarian carcinoma.
    Garner EI
    J Reprod Med; 2005 Jun; 50(6):447-53. PubMed ID: 16050569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early detection of ovarian cancer: new technologies in pursuit of a disease that is neither common nor rare.
    Bast RC
    Trans Am Clin Climatol Assoc; 2004; 115():233-47; discussion 247-8. PubMed ID: 17060970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Status of tumor markers in ovarian cancer screening.
    Bast RC
    J Clin Oncol; 2003 May; 21(10 Suppl):200s-205s. PubMed ID: 12743135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on ovarian cancer screening.
    Munkarah A; Chatterjee M; Tainsky MA
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):22-6. PubMed ID: 17218847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?
    Nossov V; Amneus M; Su F; Lang J; Janco JM; Reddy ST; Farias-Eisner R
    Am J Obstet Gynecol; 2008 Sep; 199(3):215-23. PubMed ID: 18468571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for ovarian cancer.
    MacDonald ND; Rosenthal AN; Jacobs IJ
    Ann Acad Med Singap; 1998 Sep; 27(5):676-82. PubMed ID: 9919339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions.
    Skates SJ; Horick N; Yu Y; Xu FJ; Berchuck A; Havrilesky LJ; de Bruijn HW; van der Zee AG; Woolas RP; Jacobs IJ; Zhang Z; Bast RC
    J Clin Oncol; 2004 Oct; 22(20):4059-66. PubMed ID: 15381683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population screening and early detection of ovarian cancer in asymptomatic women.
    Nelson AE; Francis JE; Zorbas H;
    Aust N Z J Obstet Gynaecol; 2009 Oct; 49(5):448-50. PubMed ID: 19780723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening.
    Menon U; Talaat A; Rosenthal AN; Macdonald ND; Jeyerajah AR; Skates SJ; Sibley K; Oram DH; Jacobs IJ
    BJOG; 2014 Dec; 121 Suppl 7():35-9. PubMed ID: 25488086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for ovarian cancer in the general population.
    Chu CS; Rubin SC
    Best Pract Res Clin Obstet Gynaecol; 2006 Apr; 20(2):307-20. PubMed ID: 16364690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection.
    Berek JS; Bast RC
    Cancer; 1995 Nov; 76(10 Suppl):2092-6. PubMed ID: 8635006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Summaries for patients. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement.
    Ann Intern Med; 2012 Dec; 157(12):I-56. PubMed ID: 23362519
    [No Abstract]   [Full Text] [Related]  

  • 13. [Program for early detection of ovarian cancer for women as prophylaxis provided at a municipal hospital].
    Cnota W; Sodowski K; Olesiak-Andryszczak M; Pilch-Kowalczyk M
    Wiad Lek; 2004; 57 Suppl 1():43-7. PubMed ID: 15884203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Origin of ovarian cancer may have implications for screening.
    Tuma RS
    J Natl Cancer Inst; 2010 Jan; 102(1):11-3. PubMed ID: 20023201
    [No Abstract]   [Full Text] [Related]  

  • 15. New frontiers for ovarian cancer risk evaluation: proteomics and contrast-enhanced ultrasound.
    Dutta S; Wang FQ; Fleischer AC; Fishman DA
    AJR Am J Roentgenol; 2010 Feb; 194(2):349-54. PubMed ID: 20093595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian cancer screening: a look at the evidence.
    Fields MM; Chevlen E
    Clin J Oncol Nurs; 2006 Feb; 10(1):77-81. PubMed ID: 16482731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential and problems of screening for ovarian cancer.
    Yokoyama Y; Higuchi T; Mizunuma H
    Eur J Gynaecol Oncol; 2005; 26(3):241-3. PubMed ID: 15991520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CA 125 as a screening test for ovarian cancer.
    Hakama M; Stenman UH; Knekt P; Järvisalo J; Hakulinen T; Maatela J; Aromaa A
    J Med Screen; 1996; 3(1):40-2. PubMed ID: 8861050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement.
    Moyer VA;
    Ann Intern Med; 2012 Dec; 157(12):900-4. PubMed ID: 22964825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on angiogenesis in the benign and malignant ovarian neoplasms with the use of color and pulsed Doppler sonography and serum CA-125, CA-19.9, CA-72.4 and vascular endothelial growth factor measurements.
    Czekierdowski A
    Ann Univ Mariae Curie Sklodowska Med; 2002; 57(1):113-31. PubMed ID: 12898913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.